Editorial overview
Pulmonary therapeutics: rethinking the regimens and re-imagining the targets

https://doi.org/10.1016/j.coph.2013.05.015Get rights and content

Section snippets

Acknowledgement

The author's work cited in this editorial has received support from NHMRC (Australia).

Alastair G Stewart is a professor of pharmacology at the University of Melbourne with extensive experience in the field of respiratory and inflammation research. He has published over 170 papers and several granted patents. He graduated PhD in 1984, held postdoctoral appointments at the Royal College of Surgeons in London and in the Department of Physiology at University of Melbourne, before taking up a role as NHMRC research Fellow and Chief Scientist at the O’Brien Institute, St Vincent's

References (5)

There are more references available in the full text version of this article.

Alastair G Stewart is a professor of pharmacology at the University of Melbourne with extensive experience in the field of respiratory and inflammation research. He has published over 170 papers and several granted patents. He graduated PhD in 1984, held postdoctoral appointments at the Royal College of Surgeons in London and in the Department of Physiology at University of Melbourne, before taking up a role as NHMRC research Fellow and Chief Scientist at the O’Brien Institute, St Vincent's Hospital Melbourne. His interests during these appointments ranged from the vascular actions of lipid inflammatory mediators to the pharmacology of airway wall remodelling. He has served on numerous peer review committees for NHMRC and the Scientific Advisory Boards of several Australian Medical Research Institutes. His current research interests focus on tissue remodelling in asthma and novel drugs targeting tissue remodelling in inflammation. His long-term interest in steroid pharmacology and particularly determinants of steroid sensitivity has also encompassed several studies in tumour biology. Prof Stewart is co-Director of the Lung Health Research Centre, at the University of Melbourne and serves as Secretary General of the Asia Pacific Federation of Pharmacologists (APFP). He is a current member of the editorial boards of Pulmonary Pharmacology and Therapeutics and Respiratory Research.

View full text